Literature DB >> 27618929

Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis.

Edoardo Ferlazzo1, Pasquale Striano2, Domenico Italiano3, Tiziana Calarese4, Sara Gasparini1, Nicola Vanni2, Floriana Fruscione2, Pierre Genton5, Federico Zara2.   

Abstract

Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis is an extremely rare condition, so far reported in a single family of Algerian origin presenting an unusual, severe form of progressive myoclonus epilepsy characterized by myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment, with probable autosomal recessive inheritance. Disease onset was between 6 and 16 years of age. Genetic study allowed to identify a homozygous nonsynonymous mutation in CERS1, the gene encoding ceramide synthase 1, a transmembrane protein of the endoplasmic reticulum (ER), catalyzes the biosynthesis of C18-ceramides. The mutation decreased C18-ceramide levels. In addition, downregulation of CerS1 in neuroblastoma cell line showed activation of ER stress response and induction of proapoptotic pathways. This observation demonstrates that impairment of ceramide biosynthesis underlies neurodegeneration in humans.

Entities:  

Keywords:  ER stress response; ceramide synthase; epilepsy; neurodegeneration; progressive myoclonus epilepsies

Mesh:

Substances:

Year:  2016        PMID: 27618929     DOI: 10.1684/epd.2016.0857

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  2 in total

1.  Downregulation of ceramide synthase 1 promotes oral cancer through endoplasmic reticulum stress.

Authors:  Wen Chen; Chenzhou Wu; Yafei Chen; Yuhao Guo; Ling Qiu; Zhe Liu; Haibin Sun; Siyu Chen; Zijian An; Zhuoyuan Zhang; Yi Li; Longjiang Li
Journal:  Int J Oral Sci       Date:  2021-03-22       Impact factor: 6.344

Review 2.  Sphingolipids: membrane microdomains in brain development, function and neurological diseases.

Authors:  Anne S B Olsen; Nils J Færgeman
Journal:  Open Biol       Date:  2017-05       Impact factor: 6.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.